Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761758 | 0.91 | FGFR1 (0.50) | FGFR1KDRGABRA1GABRG2GABRB3 | |
| SCHEMBL1761806 | 0.91 | FGFR1 (0.47) | FGFR1KDRGABRA1GABRG2GABRB3 | |
| SCHEMBL1761706 | 0.91 | FGFR1 (0.50) | FGFR1KDRGABRA1GABRG2GABRB3 | |
| SCHEMBL1761853 | 0.87 | FGFR1 (0.49) | FGFR1KDRGABRA1GABRG2GABRB3 | |
| SCHEMBL1761665 | 0.85 | FGFR1 (0.49) | FGFR1KDRGABRA1GABRG2GABRB3 | |
| SCHEMBL1762007 | 0.83 | GABRA1 (0.60) | FGFR1KDRGABRA1GABRG2GABRB3 | |
| SCHEMBL1761895 | 0.82 | GABRA1 (0.59) | FGFR1KDRGABRA1GABRG2GABRB3 | |
| SCHEMBL1761759 | 0.78 | KDR (0.48) | FGFR1KDRSRCGABRA1GABRG2 | |
| SCHEMBL1761985 | 0.77 | FGFR1 (0.63) | FGFR1SRCGABRA1GABRG2GABRB3 | |
| SCHEMBL1761770 | 0.77 | FGFR1 (0.54) | FGFR1KDRSRCGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2011-05-19 | — | — | US | claimed |
| EP-2319837-A1 | Benzimidazole derivatives and their use for modulating the GABAa receptor complex | NeuroSearch AS (DK) | 2011-05-11 | — | — | EP | claimed |
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2009-02-05 | — | — | US | claimed |
| EP-2001855-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2008-12-17 | — | — | EP | claimed |
| WO-2007110374-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | WO | claimed |
| US-8288418-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2012-10-16 | — | — | US | disclosed |
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2011-05-19 | — | — | US | disclosed |
| EP-2319837-A1 | Benzimidazole derivatives and their use for modulating the GABAa receptor complex | NeuroSearch AS (DK) | 2011-05-11 | — | — | EP | disclosed |
| US-7902230-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-03-08 | — | — | US | disclosed |
| EP-2001855-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2010-11-03 | — | — | EP | disclosed |
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-2001855-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110374-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | FGFR1 3907/4885KDR 3804/4885SRC 3745/4885 |
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | FGFR1 3907/4885KDR 3804/4885SRC 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.